Proton Rahman

Featured in: Favicon

bmj.com (+1) Favicon

biomedcentral.com Favicon

thelancet.com Favicon

futuremedicine.com Favicon

jrheum.org Favicon

onlinelibrary.wiley.com Favicon

arthritis-research.biomedcentral.com

Articles

Real-World Incidence and Determinants of Infection in Patients With Rheumatoid Arthritis Treated With Golimumab After a Median Follow-Up Time of 27 Months

Sep 1, 2023 | jrheum.org | Louis Bessette |Proton Rahman |John Kelsall |Jane Purvis

Real-World Incidence and Determinants of Infection in Patients With Rheumatoid Arthritis Treated With Golimumab After a Median Follow-Up Time of 27 Months Louis Bessette, Proton Rahman, John Kelsall, Jane Purvis, Emmanouil Rampakakis, Allen J. Lehman, Meagan Rachich, Francois Nantel, Odalis Asin-Milan, A. Marilise Marrache The Journal of Rheumatology Sep 2023, 50 (9) 1121-1126; DOI: 10.3899/jrheum.2022-1283
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis

Jun 1, 2023 | jrheum.org | Proton Rahman |Wolf-Henning Boehncke |Philip Mease |Alice Gottlieb

DISCUSSIONThese findings represent the most comprehensive safety assessment of an IL-23p19 inhibitor in PsA that we know of to date, with 1508 patients evaluated for up to 2 years (2125 PY). Integrated analyses across 4 phase II/III studies of patients with active PsA demonstrated that the safety profile of GUS remained consistent, regardless of prior TNFi or concomitant MTX use.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →